Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Baucus Wants To Keep Comparative Effectiveness Separate From Cost Control

Executive Summary

One of the first skirmishes in the 2009 health care reform debate is likely to occur over comparative effectiveness

You may also be interested in...



Baucus to Proceed With Public/Private Comparative Effectiveness Vision

Even with the inclusion of comparative effectiveness research funding in the American Recovery and Reinvestment Act, Senate Finance Committee Chairman Max Baucus is showing no signs of abandoning plans to include comparative effectiveness in the upcoming health care reform debate

Baucus to Proceed With Public/Private Comparative Effectiveness Vision

Even with the inclusion of comparative effectiveness research funding in the American Recovery and Reinvestment Act, Senate Finance Committee Chairman Max Baucus is showing no signs of abandoning plans to include comparative effectiveness in the upcoming health care reform debate

Group With Ties To Daschle Urges Release Of More Detailed Part D Data

A new report from the Center for American Progress highlights the potential value to comparative effectiveness research of Medicare Part D claims and performance data and urges the release of more detailed information on the program through administrative changes

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050308

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel